414 related articles for article (PubMed ID: 26153365)
21. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.
Horvath N; Spencer A; Kenealy M; Joshua D; Campbell PJ; Lee JJ; Hou J; Qiu L; Kalff A; Khong T; Londhe A; Siggins S; van Kooten Losio M; Eisbacher M; Prince HM
Leuk Lymphoma; 2019 Sep; 60(9):2122-2133. PubMed ID: 30777794
[TBL] [Abstract][Full Text] [Related]
22. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
Wu S; Zheng C; Chen S; Cai X; Shi Y; Lin B; Chen Y
Biomed Res Int; 2015; 2015():927105. PubMed ID: 26425561
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Roussel M; Moreau P; Hebraud B; Laribi K; Jaccard A; Dib M; Slama B; Dorvaux V; Royer B; Frenzel L; Zweegman S; Klein SK; Broijl A; Jie KS; Wang J; Vanquickelberghe V; de Boer C; Kampfenkel T; Gries KS; Fastenau J; Sonneveld P
Lancet Haematol; 2020 Dec; 7(12):e874-e883. PubMed ID: 33242444
[TBL] [Abstract][Full Text] [Related]
25. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A
J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
28. Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.
Thidemann Andersen K; Klausen T; Abildgaard N; Klarskov Andersen M; Frost Andersen N; Christian Frølund U; Helleberg C; Kjeldsen E; Pedersen P; Helm-Petersen S; Svirskaite A; Preiss B; Gimsing P; Juul Vangsted A
Am J Hematol; 2017 Oct; 92(10):E611-E614. PubMed ID: 28707398
[No Abstract] [Full Text] [Related]
29. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Kropff M; Vogel M; Bisping G; Schlag R; Weide R; Knauf W; Fiechtner H; Kojouharoff G; Kremers S; Berdel WE
Ann Hematol; 2017 Nov; 96(11):1857-1866. PubMed ID: 28905189
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Muranushi H; Kanda J; Kobayashi M; Maeda T; Kitano T; Tsuji M; Ueda Y; Ishikawa T; Nohgawa M; Watanabe M; Imada K; Moriguchi T; Itoh M; Ohno H; Yonezawa A; Hirata H; Arima N; Asagoe K; Anzai N; Nagata K; Yasuno S; Kuwabara Y; Kitao H; Kim I; Kawagishi K; Ueshima K; Tominari S; Nakayama T; Yamashita K; Takaori-Kondo A
Hematology; 2022 Dec; 27(1):239-248. PubMed ID: 35152852
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
[TBL] [Abstract][Full Text] [Related]
33. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
[TBL] [Abstract][Full Text] [Related]
34. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
35. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
Moreau P; Hebraud B; Facon T; Leleu X; Hulin C; Hashim M; Hu Y; Caillot D; Benboubker L; Zweegman S; Merz M; Weisel K; Salwender H; Mai EK; Goldschmidt H; Bertsch U; Vanquickelberghe V; Kampfenkel T; Boer C; Krotneva S; Proskorovsky I; He J; Lam A; Lee C; Cote S; Sonneveld P
Immunotherapy; 2021 Feb; 13(2):143-154. PubMed ID: 33228440
[No Abstract] [Full Text] [Related]
36. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Einsele H; Engelhardt M; Tapprich C; Müller J; Liebisch P; Langer C; Kropff M; Mügge LO; Jung W; Wolf HH; Metzner B; Hart C; Gramatzki M; Hertenstein B; Pfreundschuh M; Rösler W; Fischer T; Maschmeyer G; Kanz L; Hess G; Jäger E; Bentz M; Dürk HA; Salwender H; Hebart H; Straka C; Knop S
Br J Haematol; 2017 Nov; 179(4):586-597. PubMed ID: 28961309
[TBL] [Abstract][Full Text] [Related]
37. Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.
Ram R; Magen-Nativ H; Vidal L; Herscovici C; Peck A; Raanani P; Shpilberg O; Yeshurun M
Clin Transplant; 2012; 26(5):E549-54. PubMed ID: 23061765
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Morgan GJ; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Cook G; Feyler S; Johnson PR; Rudin C; Drayson MT; Owen RG; Ross FM; Russell NH; Jackson GH; Child JA;
Haematologica; 2012 Mar; 97(3):442-50. PubMed ID: 22058209
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Zweegman S; Caillon H; Caillot D; Avet-Loiseau H; Delforge M; Dejoie T; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Schiano de Colella JM; van de Donk NW; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Hua W; Wang J; Tuozzo A; de Boer C; Rowe M; Vanquickelberghe V; Carson R; Vermeulen J; Corre J; Sonneveld P;
Lancet Oncol; 2024 Jun; ():. PubMed ID: 38889735
[TBL] [Abstract][Full Text] [Related]
40. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.
Brioli A; Perrone G; Patriarca F; Pezzi A; Nobile F; Ballerini F; Motta MR; Ronconi S; Tacchetti P; Catalano L; Zannetti BA; Rizzi S; Volpe S; Zamagni E; Liberati AM; Mancuso K; Boccadoro M; Davies FE; Morgan GJ; Palumbo A; Cavo M
Bone Marrow Transplant; 2015 May; 50(5):673-8. PubMed ID: 25642764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
